The New India Assurance Company (NSE: NIACL) fell as much as 13.71% on Tuesday to an intraday low of ₹199.52, against Monday's close of ₹231.20, as reported by Business Standard and IANS. By midday it sat near ₹209.50, down 9.5%. IFCI went with it — low of ₹92.75 versus a ₹102.51 close.

Neither company reported anything. No results, no order win, no downgrade. What moved was the price of something neither of them is: shares in the National Stock Exchange, which doesn't trade on any exchange yet.

What happened

NSE has an IPO coming — roughly ₹30,000 crore, a pure offer for sale of 14.89 crore shares (about 6% of the exchange), SEBI's observation letter issued in early September. Because the stock isn't listed, traders price it in the grey market, and that quote gets published daily as a GMP — the rupee amount buyers will pay above the expected issue price for an unlisted allotment.

That number cracked. GMP was ₹310 on 5 September and ₹221 on 8 September — down ₹89, about 29%, in three sessions (IANS, Free Press Journal). Business Standard puts Tuesday's quote at ₹225 against ₹270–285 earlier. Different desks, same direction.

Why that hits NIACL

NIACL owns 1.42% of NSE — 3.52 crore shares. IFCI owns 52.86% of SHCIL, which owns about 4.44% of NSE. Both had been bid up for exactly that reason: NIACL ran roughly 30% and IFCI as much as 40% in the preceding weeks (IANS).

Here's the bit the headline skips. Analysts expect a band of ₹1,800–2,200 a share, with NSE changing hands at ₹1,940–2,035 in the unlisted market (Business Standard, 7 Sep). Run that on the reported figures: NIACL's 3.52 crore shares are worth about ₹6,300–7,700 crore, or 17–21% of its own ₹37,443 crore market cap. An ₹89 move in a premium quote doesn't shift that stake's value by anything close to 13%. The stake wasn't repriced today. The crowd that bought the stock for the stake left.

Is it expensive?

NIACL trades at a P/E of 48.7 on a ₹37,443 crore market cap, on last year's return on equity of 4.92%, with the government holding 85.4% (Screener.in). Nearly 49 times earnings for sub-5% ROE is rich in absolute terms — that multiple is paying for the treasury asset, not the insurance book.

Compare the obvious alternative. GIC Re, the other state-owned insurer and itself a seller in the NSE offer, trades at a P/E of 6.93 on a ₹61,439 crore market cap, 0.85 times book, with 14.6% ROE. Bigger, better returns, one-seventh the multiple, same NSE angle.

The business

NIACL is India's largest non-life insurer, founded in 1919 — motor, health, fire, marine, engineering and crop cover, with a 12.6% FY25 market share (Screener.in). Underwriting is the company. The NSE holding is a legacy balance-sheet investment that gets marked to market exactly once, at listing.

Who else this touches

• LIC holds about 10.7% of NSE and isn't selling — the largest listed holder by far, but a rounding error against LIC's own size, which is why it doesn't lurch on a GMP headline.
• SBI (up to 2.48 crore shares), Bank of Baroda and GIC Re sell into the offer — cash in, not a re-rating.
• Anyone who bought NSE in the unlisted market at the June 2025 peak of ₹2,360 is roughly 14% underwater at ₹1,940–2,035.

What flips it

The price band, which hasn't been announced — mid-September is the working expectation, listing pencilled in for late September. Land it near ₹2,200 and the proxy trade restarts in a session. Land it near ₹1,800, or let the timeline slip, and the premium left in NIACL and IFCI has nothing under it. One number, not yet public, sets both.

Scale, while that band is pending: NSE's DRHP shows FY26 revenue of ₹16,601 crore and profit after tax of ₹10,302 crore, on roughly 76% operating margins and about 93% of India's cash equity turnover. ₹30,000 crore for ~6% implies near ₹5 lakh crore for the whole exchange — about 48 times last year's profit.

As of 8 Sep 2026, ~1:00 PM IST. Prices, GMP levels and stake figures as reported by the sources cited; valuation ratios as reported by Screener.in. Sources: Business Standard, IANS, Free Press Journal, Business Standard (NSE IPO), Screener.in (NIACL), Screener.in (GIC Re), NiftyTrader (NSE DRHP shareholders & FY26 financials). For discussion and education only — not investment advice. Verify before acting.